- Home
- GRWG vs KZIA Comparison
GRWG vs KZIA Comparison
Compare GRWG & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRWG | KZIA |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.2M | 100.8M |
| IPO Year | 2015 | 2002 |
Fundamental Metrics
Financial Performance| Metric | GRWG | KZIA |
|---|---|---|
| Price | $1.28 | $13.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 645.9K | 272.9K |
| Earning Date | 05-08-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,365,479.00 | N/A |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.51 | N/A |
| 52 Week Low | $0.93 | $3.05 |
| 52 Week High | $2.40 | $17.40 |
Technical Indicators
Market Signals| Indicator | GRWG | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 56.58 | 74.57 |
| Support Level | $1.02 | $5.85 |
| Resistance Level | $1.61 | $14.42 |
| Average True Range (ATR) | 0.09 | 1.32 |
| MACD | 0.01 | 0.23 |
| Stochastic Oscillator | 42.31 | 84.64 |
Price Performance
Historical ComparisonAbout GRWG GrowGeneration Corp.
GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.